URGN: urogen.com Price/Earnings to Growth Multiple

UroGen Pharma Ltd. (URGN) focuses on urological oncology, mitigating narrow portfolio risks through the success of its first drug. The growth company undervaluation metric reflects the asset's value dynamics, where the current mark is 0.00. A unique drug delivery method provides a competitive edge, enabling the company to maintain pricing power. Meanwhile, operational stability is based on the utilization of external contract manufacturing organizations in the US and Israel.

Price/Earnings to Growth Ratio: UroGen Pharma Ltd (URGN) for 07/04/2022 - 11/15/2026

urogen.com (URGN) - metric breakdowns and financial figures

- share price and consensus valuation forecast:

Price Performance Chart UroGen|URGN - Analyst Consensus Forecast

- market capitalization information:

Market Valuation UroGen Pharma Ltd.|URGN - Real Price to Acquire Entire Company

- book value of equity indicators:

Book Value per Share UroGen Pharma|URGN - Company Book Value|Market Value to Book Value urogen.com|URGN - Company Total Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

URGN - Net Profit|Expected Net Profit UroGen Pharma Ltd.|URGN - Price to Earnings Ratio|Price to Future Earnings Ratio UroGen Pharma|URGN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation UroGen Pharma|URGN - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months UroGen Pharma|URGN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months urogen.com|URGN - Earnings growth in current year|Earnings growth forecast for next year UroGen Pharma Ltd.

- total revenue and sales volume data:

URGN - Company Revenue|Company Future Revenue UroGen Pharma Corp|URGN - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple UroGen Pharma Corp

Fundamental company analysis:UroGen Pharma Corp, URGN

Mass-produced product of UroGen Pharma Ltd.

This indicator compares the market value of a share with the growth rate of earnings per share, identifying an undervalued asset when the value falls below one. For UroGen Pharma Ltd. (URGN), which is developing innovative gel-based cancer therapies, the PEG ratio allows for an assessment of how much the current price reflects the long-term commercialization potential of these technologies.

Competitors of UroGen Pharma Ltd.